Dr. John Cush RheumNow
3 years 5 months ago
Frunevetmab (Solensia), is a cat-specific mAb against nerve growth factor was FDA approved, for use in CATS, to treat the pain of osteoarthritis. CATS! https://t.co/vY0CCMjZmC https://t.co/UnpDpo5fyB
Dr. John Cush RheumNow
3 years 5 months ago
Tomorrow! Join us for Tuesday Night Rheumatology.
Our panelists will discuss the challenges they have faced trying to manage a career and family life, as well as provide advice and strategies for managing competing priorities and obligations.
https://t.co/OlP0pupkMV https://t.co/pZQMASafcG
Dr. John Cush RheumNow
3 years 5 months ago
Abbvie has completed a phase II upadacitinib vs combo elsubrutinib/upadacitinib ( ABBV-599) in active #SLE - M19-130 (SLEek) Phase 2 trial met the primary endpoint SRI-4 response and pred dose<=10 mg qd. No new safety signals - Phase III trial planned https://t.co/6CwS2AVamH https://t.co/b4wQ6IoiOz
Dr. John Cush RheumNow
3 years 5 months ago
Gender Gap in Editors. Cross-sect study of top 10 Intl medical journals in 41 categories shows women underrepresented as editors in chief. Women editors=21%. No women editors in dentistry, oral surgery; allergy, psychiatry; anesthesiology; ophthalmology https://t.co/JWAwrO9F4w https://t.co/0viEMa6ImK
Dr. John Cush RheumNow
3 years 5 months ago
Variability in rheumatologist steroid prescribing - using data on ~500k RA pts and 6,875 rheumatologists. Those LESS likely to prescribe alot of steroids were: women, solo practitioners, in practice ≥10 years, seeing greater#s of RA pts/year https://t.co/ELk0avorOe
Dr. John Cush RheumNow
3 years 5 months ago
Open-label Trial of 14 pts with MAS due to steroid refractory systemic JIA or adult-onset Still’s demonstrated the efficacy of IV emapalumab, an anti-IFNγ mAb. Demonstrated signif reductions in LDH, sIL-2R, Ferritin, CXCL9, & steroid dose https://t.co/vgxT5KzmQF https://t.co/gDLmfOlSHG
Dr. John Cush RheumNow
3 years 5 months ago
Mom in Medicine BINGO - Just try to Win! #WIR https://t.co/Mb4KtsWQPK
The EMA has updated recommendations regarding the use of JAK inhibitors by issuing a direct healthcare professional communication summarizing the data and warnings regarding an increased risk of malignancy, major adverse cardiovascular events (MACE), serious infections, VTE, and mortality in some patients receiving JAKi for the treatment of chronic inflammatory disorders.
Origin stories have captivated me ever since my childhood spent reading Greek Mythology and Marvel comic books. Superheroes have different powers and personalities. Some could fly, others were strong and seemed invincible, most were intelligent, but all fought for the good of humanity.
Dr. John Cush RheumNow
3 years 5 months ago
LAVLI - A New Autoinflammatory Disorder NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene. https://t.co/RYmb3QFB1T https://t.co/sn5hwVxwPk
Dr. John Cush RheumNow
3 years 5 months ago
2022 EULAR Recommendations for ANCA-associated Vasculitis
EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
https://t.co/lvPO26S0k6 https://t.co/cQtiEctrTR
Dr. John Cush RheumNow
3 years 5 months ago
30 consecutive seropositive (CCP or RF+) early RA pts - 60% had pulmonary abnormalities (PA). PA correlated with presence of neutrophil activation, parameters of inflammation and RF titres. https://t.co/dsbjPhuYzf https://t.co/1Zmyqjuaxj
Dr. John Cush RheumNow
3 years 5 months ago
Autoimmune-Rheum Dz (AIRD) flares occur in 10% w/ COVID vaccination, esp in pts w/ comorbidities, autoimmune morbidities & mental health disorders & Moderna vaccine. 3453 AIRD pts who recv Vax 9.5-11.3% had clinical flares (Arthritis 62% & fatigue 59%) https://t.co/C0WA2Znixl https://t.co/vXzL8XR7kd
Dr. John Cush RheumNow
3 years 5 months ago
Tofacitinib May Reduce Interstitial Lung Disease Risk in RA
Tofacitinib (Xeljanz) in patients with RA stood out among several other biologic and targeted sDMARDs when it came to the incidence of ILD, a retrospective cohort study showed.
https://t.co/2DCn53Rk4z https://t.co/sZYhgfCU0E
Dr. John Cush RheumNow
3 years 5 months ago
Intrathecal Methotrexate for Cerebritis
Dr. Jack Cush reviews the CV advantage to walking, the OA risk with running and the eczema-OA connection; these articles and journal reports from the past week on RheumNow.
https://t.co/wTOehtaU27 https://t.co/8Xp0C6tqBe
